BioSpace

NOVEMBER 21, 2023

CRISPR gene-editing has had its first ever approval in the UK. What can patients expect the price tag to be? Will the FDA follow suit?

Gene Therapy 122

Gene Therapy Gene Editing Gene 122

BioTech 365

DECEMBER 1, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CRISPR tagging improves accuracy of model cells grown from stem cells.A team of biomedical engineers at Duke University has created a new way to turn stem cells … Continue reading →

Engineer 40

Engineer Research 40

Fierce Pharma

NOVEMBER 7, 2023

Vertex and CRISPR Therapeutics are up first with a Dec. | But on Tuesday bluebird said that Vertex’s price tag will not factor into how the Massachusetts company will price its treatment. Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month.

Gene Therapy 94

Gene Therapy Gene 94

Scienmag

DECEMBER 1, 2020

Tagging produces detailed catalog of transcription factors key to making each cell type Credit: Gersbach Lab, Duke University DURHAM, N.C. – A team of biomedical engineers at Duke University has created a new way to turn stem cells into a desired cell type by mastering the language of gene regulatory networks.

Engineer 52

Engineer Gene Bioinformatics 52

Pharmaceutical Technology

APRIL 13, 2023

Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. If approved, exa-cel would be the first FDA-approved gene therapy based on CRISPR editing.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

XTalks

DECEMBER 13, 2023

The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel). Casgevy is also the first ever CRISPR/Cas9-based therapy approved in the US. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. There has been extremely rapid progress.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147